MYH9 confers doxorubicin resistance by stabilizing GRP78 and suppressing the PERK signaling-driven apoptotic pathway in breast cancer

Jing Jiang, Tianzi You, Ziyi Zhao, Binlei Sheng, Zhanqi Sun, Xujun Li

Open source

DOI
10.3389/fonc.2026.1923603
Published
2026-10-02
Container
Frontiers in Oncology
Publisher
Frontiers Media SA
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fonc.2026.1923603,
  title = {MYH9 confers doxorubicin resistance by stabilizing GRP78 and suppressing the PERK signaling-driven apoptotic pathway in breast cancer},
  author = {Jing Jiang and Tianzi You and Ziyi Zhao and Binlei Sheng and Zhanqi Sun and Xujun Li},
  year = {2026},
  journal = {Frontiers in Oncology},
  doi = {10.3389/fonc.2026.1923603},
  url = {https://doi.org/10.3389/fonc.2026.1923603}
}

RIS

TY  - JOUR
TI  - MYH9 confers doxorubicin resistance by stabilizing GRP78 and suppressing the PERK signaling-driven apoptotic pathway in breast cancer
AU  - Jing Jiang
AU  - Tianzi You
AU  - Ziyi Zhao
AU  - Binlei Sheng
AU  - Zhanqi Sun
AU  - Xujun Li
PY  - 2026
JO  - Frontiers in Oncology
DO  - 10.3389/fonc.2026.1923603
UR  - https://doi.org/10.3389/fonc.2026.1923603
ER  - 

APA

Jiang, J., You, T., Zhao, Z., Sheng, B., Sun, Z., & Li, X. (2026). MYH9 confers doxorubicin resistance by stabilizing GRP78 and suppressing the PERK signaling-driven apoptotic pathway in breast cancer. Frontiers in Oncology. https://doi.org/10.3389/fonc.2026.1923603

Source records